REG - GSK PLC - Ris-Rez Positive Ph 3 OS Lung Cancer Data in China
RNS Number: 5431U GSK PLC 14 September 2026 Issued: 13 September 2026, London UKRis-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in ChinaGSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd., today announced positive overal…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.